Matrix Global Advisors
  • Home
  • About
  • News
  • Reports
  • Contact
  • Follow
  • Follow
The 340B Program’s Negative Impact on Pharmaceutical Innovation

The 340B Program’s Negative Impact on Pharmaceutical Innovation

Jun 5, 2025 | Analysis

As the Department of Health and Human Services considers changes to the federal 340B drug program, including switching mandatory drug manufacturer contributions from discounts to rebates, it is important for policymakers to recognize the myriad concerns with this program.

New MGA Paper Identifies Barriers to US Biosimilar Success in the Second Decade

New MGA Paper Identifies Barriers to US Biosimilar Success in the Second Decade

Mar 5, 2025 | Analysis

Alex Brill and Christy Robinson look at the US biosimilars market a decade after the first biosimilar approval.

Implications of Cannabis Legalization for the US Federal Budget

Implications of Cannabis Legalization for the US Federal Budget

Aug 14, 2024 | Analysis

While the details of future federal legislation and executive actions to legalize, regulate, and tax cannabis remain unknown, such policies could have significant impacts on the federal budget.

Alex Brill Writes to FTC Regarding Interim Pharmacy Benefit Manager Report

Alex Brill Writes to FTC Regarding Interim Pharmacy Benefit Manager Report

Aug 1, 2024 | Analysis

In July, MGA CEO Alex Brill submitted a comment letter to the Federal Trade Commission (FTC) expressing concerns about their newly released interim report.

A Balanced Plan for Fiscal Stability and Economic Growth

A Balanced Plan for Fiscal Stability and Economic Growth

Jul 23, 2024 | Analysis

Our plan seeks to achieve long-term fiscal stability and promote economic growth by aligning federal spending and revenue and pursuing market-based policy reforms.

Implications of Cannabis Legalization for the US Federal Budget

Implications of Cannabis Legalization for the US Federal Budget

Apr 12, 2024 | Analysis

Federal legislation to legalize, regulate, and tax cannabis could have significant impacts on the federal budget.

Page 1 of 912345...»Last »
  • Analysis (50)
  • Books (3)
  • Commentary (15)
  • Events (21)
  • Interviews (59)
  • News (55)
  • Op-Eds (96)
  • Press Releases (4)
  • Testimony (21)
  • effects of 304B
    The 340B Program’s Negative Impact on Pharmaceutical InnovationJune 5, 2025
  • a conversation on tax reform
    A Conversation with House Ways and Means Committee Chairman Jason Smith on Tax ReformMarch 5, 2025
  • US Biosimilars Market
    New MGA Paper Identifies Barriers to US Biosimilar Success in the Second DecadeMarch 5, 2025
  • Congress on the Brink of Disrupting the PBM Market
    Congress on the Brink of Disrupting the PBM MarketJanuary 27, 2025
  • Raising the Salt Cap Would Increase Tax Complexity
    Raising the Salt Cap Would Increase Tax ComplexityJanuary 13, 2025
  • Economics of “Delinking” Are Still Not Good
    Economics of “Delinking” Are Still Not GoodDecember 13, 2024
  • Child Tax Credit Tradeoffs
    The Child Tax Credit: Tradeoffs and PreferencesOctober 30, 2024
  • Oregon’s Measure 118 Turnover Tax
    Oregon’s Measure 118: The Turnover Tax Is the WorstOctober 29, 2024
  • Dueling Child Tax Credit Proposals
    Dueling Child Tax Credit Proposals: Harris vs. VanceOctober 21, 2024
  • Deduction for Auto Loan Interest
    Trump Proposes Bringing Back the Deduction for Auto Loan InterestOctober 16, 2024
© Copyright 2022 Matrix Global Advisors | Design By DreamBig Creative
MGA
  • Home
  • About
  • News
  • Reports
  • Contact